Accium BioSciences

United States
Seattle, United States, Washington
206.258.8860 ★

Company profile

Accium BioSciences company profile

Developer of an ultrasensitive detection platform designed to overcome challenges faced in clinical development of novel drugs. The company's ultrasensitive detection platform investigates pharmacologic and pharmacodynamic endpoints of Merck's Temodar® in glioblastoma multiforme (GBM) patients, providing 14C-methylation measurements of tumor DNA after 14C-Temodar® administration. The purpose of the study is to identify pharmacologic or pharmacodynamic endpoints that may be predictive of response to therapy in individual patients, enabling clinicians to involve therapeutic response prediction and resistance to treatment.

Business identity

Contact email
[email protected]
Phone number
206.258.8860
Operating status
Active
Company type
For Profit
Employee range
00001-00010 employees
Revenue range
$1K+
Founded
2004-05-01

Headquarters

Headquarters
Seattle, United States, Washington
Postal code
98122
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
Seed
Funding rounds
1
Total equity funding
$3M
Last funding
Seed / $3M / 2006-01-09
Last equity funding
Seed / $3M
Investors
1
Lead investors
1

Founders and investors

Lead investors

WRF Capital

Investors

WRF Capital

People at this company

Preview only. Contact details are available after you sign in.

Log in to view people and contact details at this company

Contact information and company affiliations may no longer be accurate. Verify details before reaching out.

Shipment data

Explore detailed shipment data

Sign in to view shipment history, products, suppliers, and trade lanes for this company.

Log in to view shipment data

Shipment records and coverage can change as the dataset is updated.